Topic Listing for Pfizer

Access Notice Annual Meeting Proxy Statement 2007 Financial Access Notice Annual Meeting Proxy Statement 2008 Financial
Accountholders Accounting Policies
Acquisition Wyeth Acquisition-related Costs
Acquisition-related In-process Research Development Charges Acquisition-related In-process Research Development Charges Restructuring Costs
Acquisitions Acquisitions Dispositions Licensing Collaborations
Actual Pro Forma Impact Acquisition Adapting Scale Productivity Initiative
Additional Information Restated Plan Adjusted Diluted Eps 061 Compared 068 Year-ago
Adjusted Income Adjusted Income Diluted Eps
Adjusted Income Diluted Eps Results Adjusted Revenue Income Diluted Eps Results
Adjusted Revenues Income Diluted Eps Results Adjustment Prior Liabilities Product Returns
Administration Administration Duration
Adoption New Accounting Policies Adoption New Accounting Policy
Adoption New Accounting Standard Adoption New Accounting Standards
Advertising Costs Agenda
Agreement Acquire Wyeth Aircraft
Airport Alteration Amendment Repeal
Amended Effective 2009 Amendment Change Control Severance Agreement
Amendment Repeal Modification Foregoing Provisions Shall Not Adversely Amendment Revocation
Amendments Termination Amortization Impairments
Amortization Intangible Assets Depreciation Certain Long-lived Animal Health
Animal Research Annual Board Self-evaluation
Annual Board Self-evaluation Direction Corporate Governance Committee Prepare Annual Cash Incentive Awards
Annual Committee Self-evaluation Annual Committee Self-evaluation Each Responsible Preparing Performance Policy
Annual Incentive Criteria Annual Meeting Admission
Annual Meeting Attendance Annual Meeting Attendance Board Members Expected Attend Shareholders
Annual Meeting Webcast Appendix Letter Resignation Letterhead 2009 Board Directors Pfizer
Applicability Approve Appropriate Provision Information Board Such Meeting Agendas
Aricept Aricept Donepezil Hydrochloride
Arthritis Pain Asbestos
Asset Impairment Charge Asset Impairment Charge Other Costs Associated Suspension Bextra
Asset Impairment Charges Other Costs Associated Exiting Exubera Atlanta Georgia 30354
Audit Committee Audit Committee Financial Experts
Audit Committee Report Audit Committees Report
Audit Non-audit Fees Authentication Effectuation
Authorize Retention Outside Advisors Consultants Authorized Shares Classes Stock
Authorized Signatures Completed Vote Counted Date Sign Below Average Wholesale Price Litigation
Basis Presentation Benchmarking
Beneficial Owners Beneficial Ownership Reporting Compliance
Bextra Certain Other Drugs Bextra Certain Other Investigations
Biopharmaceutical Revenues Biotechnology Products
Board Committee Membership Board Committee Self-evaluation
Board Directors Recommends Vote Against Proposals Board Directors Shareholders Pfizer Inc
Board Directors Unanimously Recommends Vote Against Proposal Board Directors Unanimously Recommends Vote Proposal Approve Restated
Board Directors Unanimously Recommends Vote Ratification Kpmg Llp Board Materials
Board Meetings Board Policy Pension Benefits Executives
Board Size Brands
Business Business Development Activities
Business Revenues Business Segments
Businessweek Caduet
Caduet Atorvastatin Amlodipine Combination Campto
Camptosar Car Driver
Cardiovascular Metabolic Diseases Cash Compensation
Cash Equivalents Cash Equivalents Statement Flows
Cash Flows Celebrex
Celebrex Bextra Celebrex Bextra Matters
Celebrex Celecoxib Central Nervous System Disorders
Ceo Compensation Evaluation Executive Performance 2006 Ceo Performance
Ceo Performance Goals Annual Evaluation Ceo Performance Objectives
Certain Adjustments Certain Charges
Certain Definitions Certain Product Litigation--celebrex Bextra
Certain Product Litigation-celebrex Bextra Certain Relationships Related Transactions Director Independence
Certain Significant Certification Chief Executive Officer Pursuant 1350 Adopted 906
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act Certification Chief Financial Officer Pursuant 1350 Adopted 906
Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act Cfo Severance Agreement
Chairman Ceo Change Control Provisions
Change Cost Sales Change Director Occupation
Change Revenues Segment Geographic Area Change Selling Informational Administrative Sia Expenses Research Development
Changes Global Financial Markets Changes Internal Controls
Changes Laws Accounting Standards Changing Business Environment
Changing Business Environment Industry Chantix Champix
Charges Earnings Resulting Application Purchase Method Accounting Adversely Charges Related Exubera
Charter Charter Lead Independent Director
Clavamox Synulox Code 162 Provisions
Code Conduct Directors Collaborative Arrangements
Commercial Other Matters Committees
Committees Additional Functions Common Stock
Communication Stakeholders Communications Directors
Compensation Actions Compensation Committee
Compensation Committee Actions Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Consultant
Compensation Including 2007 Actions Compensation Non-employee Directors
Competition Competitive Positioning-applying Compensation Framework Executive Positions
Competitive Positioning-creating Executive Compensation Framework Competitive Products
Compliance Comprehensive Income
Consent Independent Registered Public Accounting Firm Consolidation Basis Presentation
Consumer Commercial Matters Contingencies
Contractual Obligations Controls Procedures
Corporate Governance Committee Cost Expense Control Unusual Events
Cost Sales Cost Sales Inventories
Cost-reduction Initiatives Costs Expenses
Count Vote Count Votes
Credit Ratings Credit Risk
Criteria Board Membership Cumulative Effect Change Accounting Principles
Cumulative Voting Currency Translation
Dallas Morning News Debt Capacity
Dectomax Deductibility Awards
Deferral Awards Deferred Compensation Plan Deferral Opportunities
Deferral Performance Shares Other Awards Deferred Compensation
Defined Contribution Plans Definitions
Definitive Bearer Security Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Departure Former Chief Executive Officer Departure Katen
Dependence Key In-line New Products Dependence Key In-line Products
Derivative Financial Instruments Derivatives Trading
Description Description Business
Description Transaction Designations Powers Preferences Rights Respect Shares Preferred Stock
Determination Independence Determinations Board Directors
Detrol Detrol Tolterodine
Developed Technology Rights Development Regulatory Approval Marketing Products
Did Receive Proxy Materials Differ Materially Past Results Those Anticipated Estimated Projected
Differences Between Restated Plan Original Difficulties Wholesale Distributors
Director Access Corporate Independent Advisors Director Compensation
Director Independence Director Orientation Continuing Education
Director Qualification Standards Director Service Other Public Boards
Directors Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disclosure Analysis 2008 Form 10-k Annual Report Shareholders
Disclosure Controls Discounted Awards
Dispositions Diversified
Diversified Revenues Diversified Segment
Dividends Dividends Common Stock
Documents Incorporated Reference Don Cornwell
Draxxin Duties Responsibilities
Early Retirement Provisions East Nashville Tennessee
East Ohio Effective Tax Rate
Effexor Venlafaxine Hcl Extended Release Capsules Election Directors
Elements Executive Compensation Elements Total Compensation
Eligibility Employee Benefit Trust
Employee Stock Ownership Plans Employees
Enbrel Endocrine Disorders
Enhanced Commercial Operating Structure Entitled Vote Annual Meeting
Environmental Law Compliance Environmental Matters
Equity Award Allocations Equity Award Target Values
Equity Common Stock Equity Compensation Plan Information
Estimated Benefits Termination Following Change Control Estimated Payments Severance Change-in-control
Estimated Separation Payments Termination Due Restructuring Estimated Termination Payments
Estimates Estimates Assumptions
Euro2000000000 4750 Per Cent Notes Due 2016 Everance Agreement
Everance Following Change-in-control Evergreen Provision
Exact Name Registrant Specified Charter Excede
Exchange Interests Temporary Global Security Permanent Execution Parties
Executive Commentary Executive Committee
Executive Compensation Executive Compensation Tables
Executive Long-term Incentive Grant Executive Officers
Executive Sessions Executive Sessions Directors
Executive Severance Plan Executive Summary Compensation Actions
Exhibits Expectations 2009
Expenses Experimental Animal Care
Expiration Rights Agreement Exubera
Facearial Size410 Inventories Fail Realize Anticipated Benefits Acquisition
Failure Complete Acquisition Negatively Impact Stock Price Future Failure Realize Anticipated Benefits Acquisition Wyeth
Fair Value Fair Value Consideration Transferred
Fifth Financial Condition Liquidity Capital Resources
Financial Data Financial Guidance
Financial Guidance 2010 Financial Instruments
Financial Instruments Derivative Hedging Activities Financial Instruments Derivative Hedging Activities Foreign Exchange Risk
Financial Report Financial Restatement
Financial Risk Management Financial Statement Schedules
Financial Statements Financial Statements Supplementary Data
Financial Summary Financial Targets 2012
Financing Activities Following Information Reflects Kindlers Performance Evaluation Resulting Process
Forbes Foreign Currency Translation
Foreign Exchange Risk Form
Form 10-k Form Coupon
Form Permanent Global Security Representing Euro Notes Due Formation Viiv Equity-method Investment
Former Ceo Director Former Non-employee Director Compensation Plan
Forward-looking Information Factors Affect Future Results Full-year 2007 Revenues 486 Increased 484 2006
Function Liaison Chairman Further List Description Risks Uncertainties Other Matters Found
General General Description Adjusted Income Measure
General Industry Comparator Group General Provisions
General Terms Conditions Euro Notes Due 2013 General Terms Conditions Euro Notes Due 2016
General Terms Conditions Euro Notes Due 2021 Generic Competition
Generic Products Genotropin
Geodon Zeldox Global Economic Conditions
Goodwill Goodwill Other Intangible Assets
Goodwill Other Intangibles Governing Law
Government Investigations Government Investigations Requests Information
Government Regulation Managed Care Trends Government Regulation Price Constraints
Grandfathered Benefits Grants Restated Plan
Guarantees Indemnifications Guarantor
Guidelines Policy Laboratory Animal Care Health Care Reform
Historical Grant Information Hormone-replacement Therapy
I-75 Northbound Florida Macon Savannah I-75 Southbound Marietta Canton Chattanooga Nashville
I-85 Northbound Columbus Montgomery I-85 Southbound Downtown Area
Ign-on Bonus Replacement Compensation Impact Foreign Exchange Revenues
Impact Net Income Impact Repatriation Foreign Earnings
Importation Cases Improvac
In-process Research Development In-service Post-employment Benefits
Incentive Stock Options Income Continuing Operations
Income Tax Contingencies Incremental Cost Perquisites Provided Named Executive Officers
Incur Significant Transaction Acquisition-related Costs Connection Acquisition Indemnification
Indemnification Severance Indenture
Independence Independence Audit Compensation Corporate Governance Committees Consist Only
Independent Board Chairman Index
Industry-specific Challenges Infectious Respiratory Diseases
Information Technology Inspra
Insurance Insurance Plan Costs 2007
Insurance Plans Integration Costs
Intellectual Property Rights Interest Rate Foreign Exchange Risk
Interest Rate Risk Internal Communication Regarding Goodmans Resignation
Internal Control Over Financial Reporting International Operations
Introduction Inventories
Investing Activities Investments
Investments Debt Equity Securities Investments Loans Derivative Financial Instruments
Isin Xs0432070752 Common Code 043207075 Isin Xs0432071131 Common Code 043207113
Issuer Purchases Equity Securities Jeffrey Kindler
Jpmorgan Chase Bank Katens Outstanding Prorated Performance Shares 2006
Key Component Compensation Key Provisions Restated Plan
Kpmg Llp Lead Independent Director
Lease Commitments Legacy Warner-lambert Equity Compensation Plans
Legal Proceedings Legal Proceedings Contingencies
Licensing New Business Development Strategy Recent Transactions Limit Awards Individual
Limit Awards Restated Plan Limit Awards Without Restriction
Limitation Reuse Shares Limitations Relative Rights Powers Respect Shares Common Stock
Lipitor Lipitor Atorvastatin
Lipitor Celebrex Detrol Caduet List Shareholders Entitled Vote Annual Meeting
Located Outside Puerto Rico Canada See Proxy Card Long-lived Assets
Long-term Debt Issuance Long-term Debt Redemption
Long-term Equity Incentive Awards Looking Ahead
Lyrica Lyrica Pregabalin
Mail Majority Vote Policy
Managed Care Organizations Managements Discussion Analysis Financial Condition Results Operations
Managements Report Managements Report Internal Control Over Financial Reporting
Market Market Business Conditions
Market Common Equity Related Stockholder Matters Issuer Purchases Marketable Securities
Marketing Mckinnells Outstanding Prorated Performance Shares 2006
Meeting Conduct Meetings
Membership Merger Agreement Between Pfizer Wyeth
Merger Not Accretive Cause Dilution Earnings Per Share Merger-related Costs
Minimum Performance Period Minimum Price Required
Minimum Restriction Period Mirapex
Miscellaneous Modifications Executive Compensation Program
Monsanto-related Matters Name Person Filing Proxy Statement Other Registrant
Named Executive Officer Performance Naxcel Excenel Rtu
Need Ticket Attend Annual Meeting Net Financial Assets
Neurontin Neurontin Gabapentin
New Accounting Standards New Approach Research
New Cost-reduction Initiative New Medicines Patients
Ninth Non-employee Director Compensation
Non-employee Director Compensation Plan Non-qualified Stock Options
Non-voting North Michigan
North Saint Louis Missouri Norvasc
Norvasc Amlodipine Notes
Notice 2007 Annual Meeting Shareholders Notice Annual Meeting Shareholders
Notice Period Notices
Number Number 1-3619
Off-balance Sheet Arrangements Officers
Officers Directors Oncology
Ongoing Planned Clinical Trials Additional Uses Dosage Forms Ontinuing Named Executive Officers
Operating Activities Operating Environment
Operating Environment Response Key Challenges Operating Environment Response Key Opportunities Challenges
Ophthalmology Option Exercises Stock Vested Table
Optional Redemption Notes Sinking Fund Original Issue Amount Notes
Other Other Business Shareholders
Other Income Deductions Other Income Deductions-net
Other Indication Reverse Side Form Proxies Vote Voting Other Matters
Other Matters Decided Annual Meeting Other Named Executive Officers Performance Objectives
Other Offices Corporation Also Office City State New Other Perquisites
Other Responses Industry-specific Challenges Other Stock Unit Awards
Outside United States Overall Economic Environment
Ownership Requirements Part
Part Other Information Participate Flow Information Board Such Meeting Agendas Schedules
Particular Covenants Patent Matters
Patents Intellectual Property Rights Pay Cost Proxy Solicitation
Payments Payments Death
Payments Disability Peer Group Performance Graph
Pension Plan Assumptions Pension Postretirement Benefit Plans
Pension Postretirement Benefit Plans Defined Contribution Performance
Performance Annual Incentive Award Performance Awards
Performance Share Award Program Relative Payout Matrix Performance Share Awards
Performance Share Awards Relative Payout Matrix Perquisites
Person Annual Meeting Pfizer
Pfizer Announces Retirement Vice Chairman David Shedlarz Pfizer Completes Acquisition Wyeth
Pfizer Corporate Governance Website Pfizer Inc
Pfizer Inc Annual Retainer Unit Award Plan Pfizer Inc Euro1850000000 3625 Per Cent Notes Due
Pfizer Inc Permanent Global Security £1500000000 6500 Per Pfizer Inc Temporary Global Security Euro1850000000 3625 Per
Pfizer Inc Temporary Global Security Euro2000000000 5750 Per Pfizer Inc Temporary Global Security £1500000000 6500 Per
Pfizer Inc Working Together Healthier World8482 Pfizer Inc £1500000000 6500 Per Cent Notes Due
Pfizer Policies Business Ethics Conduct Pfizer Ranbaxy Settle Lipitor Patent Litigation Worldwide Receive
Pfizer Reports 2008 Results Pfizer Reports Full-year 2008 Results 2009 Financial Guidance
Pfizer Reports Full-year 2009 Results Provides 2010 Financial Pfizer Retirement Annuity Plan
Pfizer Savings Plans Pfizer Shows Accelerating Pipeline Significant Growth Late-stage Clinical
Pfizer Website Pharmaceutical
Pharmaceutical Revenues Pharmaceuticals
Pharmacia Cash Balance Pension Plan Philosophy Goals Executive Compensation Program
Place Meetings Records Directors Hold Keep Books Corporation Plan Administration
Plan Benefits Policy Audit Committee Pre-approval Permissible Non-audit Services Independent
Policy-criteria Selection Compensation Committee Consultant Pondimin
Post-approval Data Potential Payments Termination Change-in-control
Preferred Stock Prempro
Prescription Preside Executive Sessions
President Absence Chair Board Vice Shall Preside Meetings Pricing Access
Principal Accountant Fees Services Principles Objectives Executive Compensation Program
Prior-period Acquisitions Pristiq
Product Competition Product Descriptions Viagra
Product Developments Product Liability Matters
Product Litigation Product Manufacturing Marketing Risks
Product Performance Promise Pay
Properties Property Plant Equipment
Proposal Proposed Amendments
Protonix Protonix Pantoprazole Sodium
Provision Taxes Income Proxy Solicited Board Directors
Proxy Statement Pursuant Securities Proxy Statement Pursuant Securities Exchange Act 1934 Amendment
Proxy Statement Required Purchase Accounting Adjustments
Purpose Pursuant 906 Sarbanes-oxley Act 2002
Qualifications Director Nominees Quantitative Qualitative Disclosures Market Risk
Ratification Independent Registered Public Accounting Firm Ratification Kpmg
Raw Materials Receive Future Proxy Materials Electronically
Recent Compensation Committee Actions Recent Fda Approvals
Recently Adopted Accounting Standards Recently Completed Performance Periods-previous Performance-contingent Share Award Program
Recently Issued Accounting Standards Recently Issued Accounting Standards Not Adopted 2006
Recently Issued Accounting Standards Not Adopted 2007 Recently Issued Accounting Standards Not Adopted 2008
Recently Issued Accounting Standards Not Adopted 2009 Recommend Outside Advisors Consultants
Reconciliation Reconciliation 2008 Adjusted Income Diluted Eps Guidance Reported
Redemption Option Reduce Printing Mailing Costs
Refacto Xyntha Registrants Telephone Number Including Area Code Securities Registered
Regulatory Environment Pipeline Productivity Related Person Transactions
Relevant Clearing Systems Report
Report Independent Registered Public Accounting Firm Consolidated Financial Report Independent Registered Public Accounting Firm Internal Control
Report Internal Control Over Financial Reporting Reported Net Income Diluted Eps
Required Consent Required Regulatory Approvals Not Obtained Contain Materially Burdensome
Requirements Including Deadlines Submission Proxy Proposals Nomination Directors Research Development
Research Development Expenses Research Development Expenses Acquisition-related In-process Charges
Research Development Investment Research Product Development
Research Studies Resolved
Response Responsibilities
Restricted Stock Restricted Stock Unit Awards
Restricted Stock Units Rsus Restrictions Certain Actions
Restructuring Charges Certain Acquisition-related Costs Retiree Healthcare Benefits
Retirement Savings Plans Revenue Recognition
Revenues Revenues Business Segment
Revenues Major Pharmaceutical Products Review Related Person Transactions
Revolution Rezulin
Right Indemnification Corporation Shall Indemnify Hold Harmless Fullest Rimadyl
Risks Affecting International Operations Role Composition Board Directors
Salaries Salaries Target Annual Cash Incentive Bonus Amounts
Salary Sales Deductions
Sarbanes-oxley Act 2002 Science Technology Committee
Scope Responsibilities Securities
Securities Litigation Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Segment Geographic Revenue Information
Segment Geographic Revenue Information Business Segments Selected Financial Data
Selected Measures Liquidity Capital Resources Selection Criteria
Selling Informational Administrative Expenses Selling Informational Administrative Sia Expenses
Senior Management Performance Goals Setting Compensation Targets
Setting Performance Objectives Seventh
Severance Arrangements Departure Former Executive Officers Share-based Payments
Shareholder Communication Shareholder Proposal Relating Cumulative Voting
Shareholder Proposal Requesting Report Feasibility Shareholder Proposal Requesting Report Rationale
Shareholder Proposals Shareholders Record
Shares Subject Award Shares Subject Plan
Shipping Handling Costs Short-term Borrowings
Signatures Significant Accounting Policies Consolidation Basis Presentation
Significant Accounting Policies Revenues Size3 Lease Commitments
South South Birmingham Alabama
South Indianapolis South Jackson Mississippi
Special Shareholder Meetings Specialty Pharmaceuticals
Statement Nick Rossi Statement William Steiner
Stephen Sanger Elected Pfizers Board Directors Stock
Stock Appreciation Rights Stock Appreciation Rights Sars
Stock Awards Stock Option Grant Policy
Stock Option Repricing Exchange Stock Options
Stock Ownership Stock Ownership Requirements
Stock Unit Awards Performance Stock-based Compensation Costs
Stockholder Vote Required Strategic Initiatives-strategy Recent Transactions
Submission Matters Vote Security Holders Subsequent Event
Subsidiaries Succession Planning
Supplemental Release Claims Supplmental Indenture
Supporting Statement Sutent
Table Contents Take Substantial Additional Indebtedness Finance Acquisition
Tax Accounting Policies Tax Contingencies
Tax Deductibility Pay Tax Matters
Tax Rate Reconciliation Tax Reporting Personal Aircraft
Tax Reporting-personal Aircraft Tax Treatment Awards Non-employee Directors Employees Outside United
Tax Treatment Options Awards Taxes Income
Telephone Internet Term Limits
Term Plan Terminated Change-in-control Agreements
Terrorist Activity Therefore
Thimerosal Thursday 2008 830 Central Daylight Time Peabody Memphis
Total Revenues Business Segment Total Shareholder Return Units Tsrus
Totally Unrelated Performance Trade Secrets Action California
Trading Pfizer Stock Derivatives Transactions Related Persons
Transferability Trimegestone
Trovan Truly
Trustee Tygacil Tigecycline
Uncertainty Relating Cox-2 Medicines Undertake Obligation Publicly Update Forward-looking Statements Whether Result
United States Urology
Various Drugs Vfend
Vfend Voriconazole Viagra
Vote Vote Pfizer Shares
Voting Directors West Chicago
West Little Rock Arkansas What Change Mind After Vote Shares
What Difference Between Holding Shares Shareholder Record Beneficial What Householding Affect
What Shares Included Proxy Card What Voting Requirements Elect Directors Approve Each Proposals
Wyeth Wyeth Acquisition
Wyeth Faces Litigation Risks Subject Various Legal Proceedings Xalacom
Xalatan Xalatan Xalacom
Zithromax Zoloft
Zoloft Effexor Zosyn
Zyrtec Zyvox
Zyvox Linezolid 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki